Misonix (NASDAQ:MSON) was upgraded by TheStreet from a “d+” rating to a “c” rating in a note issued to investors on Tuesday, TheStreetRatingsTable reports.
MSON stock opened at $19.04 on Tuesday. The firm has a market cap of $331.14 million, a PE ratio of -13.04 and a beta of 1.48. The company has a quick ratio of 2.43, a current ratio of 3.13 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average of $18.80 and a 200-day moving average of $14.57. Misonix has a 12-month low of $9.06 and a 12-month high of $20.71.
Misonix (NASDAQ:MSON) last released its earnings results on Thursday, February 4th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.22. The company had revenue of $18.26 million during the quarter. Misonix had a negative return on equity of 16.94% and a negative net margin of 35.03%.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: Benefits of owning preferred stock
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.